Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT

Article Abstract:

A combination of the drug AZT (zidovudine) and an experimentally altered cytokine inhibitor called S9a strongly inhibit replication of HIV in cell cultures. Researchers obtained the S9a molecule from Canventol, an inhibitor of tumor necrosis factor-alpha (TNF-alpha). S9a was as effective as AZT at viral inhibition when used alone. Combined, the two agents acted against both the virus and the host cells to prevent successful duplication of the virus. Application of such drug combinations may help prevent the development of drug-resistant strains of HIV in infected patients.

Research, Physiological aspects, HIV infection, Drug therapy, HIV infections, Tumor necrosis factor, Zidovudine, Drug therapy, Combination, Combination drug therapy

---

Canventol inhibits HIV-1 replication by a Tat-induced TAR-independent mechanism

Article Abstract:

The drug canventol can block HIV reproduction induced by the Tat protein but this inhibition is independent of the trans-activator response (TAR). Tat usually interacts with TAR, which is an RNA sequence, to activate viral reproduction. The effect of canventol seems to result from inhibition of tumor necrosis factor (TNF), since canventol inhibition can be reversed by TNF. Canventol is effective at very small concentrations, indicating that it could be a very useful drug against HIV.

Evaluation, Antiviral agents

---

Similar abstracts:

• Abstracts: Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa-B action

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.